Clinical Report: Baptist Health Oncologist Rohan Garje Recognized for National Leadership in Cancer Treatment Guidelines

Overview

Rohan Garje, M.D., chief of genitourinary medical oncology at Baptist Health Herbert Wertheim Cancer Institute, received the Fellow of the American Society of Clinical Oncology (FASCO) designation in July 2026 for sustained volunteer service. Since 2022, he has chaired ASCO’s metastatic prostate cancer guideline development group, including work on major updates issued in 2022 and 2025. ASCO’s metastatic castration-resistant prostate cancer guidance now uses a living guideline model, with recommendations reviewed as new evidence emerges.

Background

ASCO develops clinical practice guidelines to help oncologists assess evidence and inform cancer treatment decisions. Metastatic castration-resistant prostate cancer (mCRPC) is advanced prostate cancer that progresses despite treatment to suppress testosterone. The source describes ASCO’s 2025 update as focused on systemic therapy for mCRPC and notes that Garje was its lead author. ASCO has adopted a living guideline approach for this guidance, enabling expert review of emerging research and revision of recommendations when warranted.

Data Highlights

Key Findings

• Garje received the FASCO designation in July 2026 in recognition of sustained volunteer service to ASCO.
• He has chaired ASCO’s metastatic prostate cancer guideline development group since 2022 and led work associated with updates issued in 2022 and 2025.
• The 2025 ASCO guideline, published in the Journal of Clinical Oncology, addresses systemic therapy for mCRPC and lists Garje as lead author.
• ASCO’s living guideline model provides for ongoing expert review of new evidence and updates when changes to recommendations are warranted.
• Garje has contributed to ASCO work on mismatch repair and microsatellite instability testing, metastatic melanoma and head and neck cancer guidance, and somatic genomic testing recommendations.
• ASCO’s 2026.1.4 living guideline organizes systemic treatment options by prior hormone therapy, chemotherapy, and androgen receptor pathway inhibitor exposure; its editorial coverage describes updates informed by recent phase III evidence.

Clinical Implications

The source describes ASCO’s mCRPC recommendations as evidence-based guidance intended to help physicians inform treatment decisions, with the living model allowing recommendations to be reconsidered as research becomes available. The 2026.1.4 guideline context specifies that treatment options are organized according to prior therapy exposures; clinicians should consult the current guideline for its recommendations and applicable patient context.

Conclusion

Garje’s FASCO designation recognizes his volunteer contributions to ASCO, including leadership in metastatic prostate cancer guideline development. His work spans guideline updates, processes for maintaining current recommendations, and other ASCO clinical and professional initiatives.

Related Resources & Content

1. American Society of Clinical Oncology, Journal of Clinical Oncology, 2026 — Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4
2. The ASCO Post, 2022 — ASCO Honors 2022 Special Awards Recipients
3. The ASCO Post, 2014 — Residents Association Recognizes 57 Mentors and Teachers With 2014 Educator of the Year Award
4. The ASCO Post, 2012 — Oncology Professionals and Leaders to be Honored at ASCO Annual Meeting
5. ASCO Publications — Implementation of Guideline-Based Clinical Practice at Ocean Road Cancer Institute in Tanzania
6. Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4
7. Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
8. Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I: Evaluation and Treatment of Biochemically Recurrent (Following Exhaustion of Local Therapy) and Metastatic Hormone-Sensitive Prostate Cancer
9. Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4 | Journal of Clinical Oncology
10. Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer - PMC
11. Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I: Evaluation and Treatment of Biochemically Recurrent (Following Exhaustion of Local Therapy) and Metastatic Hormone-Sensitive Prostate Cancer.